United Therapeutics Corporation (NASDAQ:UTHR) Receives $509.50 Average Price Target from Analysts

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $509.50.

A number of analysts recently commented on UTHR shares. Morgan Stanley set a $447.00 price target on United Therapeutics in a research report on Wednesday, October 29th. Royal Bank Of Canada lifted their price target on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. UBS Group boosted their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $469.89, for a total transaction of $3,900,087.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $17,283,024.09. This trade represents a 18.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 597,814 shares of company stock worth $280,924,148. Company insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth approximately $29,000. Abich Financial Wealth Management LLC acquired a new position in shares of United Therapeutics during the 3rd quarter worth approximately $44,000. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. lifted its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $471.99 on Friday. The stock has a market cap of $20.32 billion, a price-to-earnings ratio of 17.89, a PEG ratio of 2.47 and a beta of 0.84. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $519.99. The firm’s 50-day simple moving average is $486.53 and its 200 day simple moving average is $406.79.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same period in the prior year, the firm posted $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.